Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30023557 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL27631447 | 0.88 | KMT2A (0.56) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL5778958 | 0.86 | CHRNB2 (0.54) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL217722 | 0.86 | LMNA (0.57) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL10753064 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL30601989 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL27468480 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL7939211 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4ALDH1A1MEN1POLB | |
| SCHEMBL4754189 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4ALDH1A1MEN1KMT2A | |
| SCHEMBL15498194 | 0.82 | KMT2A (0.66) | ALDH1A1MEN1POLBKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069679-A | N- (substituted phenyl) thiazole phenoxyacetamide compound and preparation method and application thereof | 湖南省农业生物技术研究所 | 2023-11-17 | — | — | CN | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9913842-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| EP-0060119-A1 | Azetidinone compounds and their preparation | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
| US-4329454-A | Cephalosporin compounds | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
| US-4301280-A | Preparation of 3-substituted cephalosporins | LILLY INDUSTRIES LIMITED (GB) | 1981-11-17 | — | — | US | disclosed |
| EP-0019401-A1 | Process for preparing enamine derivatives, compounds so produced and process for preparing a 3-hydroxy-cephalosporin | Lilly Industries Limited (GB) | 1980-11-26 | — | — | EP | disclosed |
| US-4176231-A | Process for preparing 3-exomethylenecepham sulfoxides | LILLY INDUSTRIES LIMITED (GB) | 1979-11-27 | — | — | US | disclosed |
| US-4159266-A | AZETIDINONE SULFINIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4052387-A | METHOD OF PREPARATION OF 3-METHYLENECEPHAMS | ELI LILLY AND COMPANY (US) | 1977-10-04 | — | — | US | disclosed |
| US-4048160-A | Process for preparation of 7-alkoxy-3-bromomethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4048163-A | Process for preparation of 7-alkoxy-3-chloromethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4042585-A | Process for preparation of 3-halomethylcephems | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CHRNB2 1051/4885CHRNA4 794/4885ALDH1A1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.